OrbusNeich Medical Group Holdings Limited (6929) AI Stock Analysis

• Market Cap: HK$3.71B
• Dividend Yield: 2.15%
• Average Volume (3M): 215.20K
• Price to Earnings (P/E): 11.7
• Beta (1Y): 0.76
• Revenue Growth: 11.06%
• EPS Growth: 5.03%
• Country: HK
• Employees: 1,331
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.19
• Shares Outstanding: 827,968,300
• 10 Day Avg. Volume: 93,750
• 30 Day Avg. Volume: 215,200
• PEG Ratio: -0.90
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 2.41
• P/FCF Ratio: 214.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: HK$5.00 ▲(12.61% Upside)

OrbusNeich Medical's strong financial performance, characterized by robust revenue growth and profitability, is the primary driver of the stock score. The technical analysis suggests a neutral market position, while the valuation indicates reasonable pricing with a decent dividend yield. The lack of recent cash flow data and declining ROE are concerns that slightly temper the overall score.

OrbusNeich Medical Group Holdings Limited Business Overview & Revenue Model

Company Description

OrbusNeich Medical Group Holdings Limited (6929) is a global medical device company specializing in the development, manufacturing, and commercialization of innovative solutions for the treatment of coronary and peripheral vascular diseases. The company operates primarily in the cardiovascular sector, providing a range of products including stents, balloon catheters, and guidewires that enhance patient outcomes in minimally invasive procedures. With a focus on research and development, OrbusNeich aims to address unmet clinical needs and improve the efficacy of vascular interventions.

How the Company Makes Money

OrbusNeich generates revenue primarily through the sale of its medical devices and products used in cardiovascular procedures. The company has established a diverse revenue model that includes direct sales to hospitals and healthcare providers, as well as distribution agreements with various medical device distributors worldwide. Key revenue streams include the sale of stents, balloon angioplasty devices, and other related vascular intervention tools. Additionally, the company may benefit from strategic partnerships with healthcare organizations and research institutions, which can lead to joint ventures, co-development of new products, and expanded market reach, contributing to its overall earnings.

OrbusNeich Medical Group Holdings Limited Financial Statement Overview

Summary

OrbusNeich Medical shows strong revenue growth and solid profitability with efficient cost management. The balance sheet is stable with low leverage and strong equity ratios, though declining ROE and lack of recent cash flow data are concerns.

Income Statement

OrbusNeich Medical has demonstrated strong revenue growth, with revenues increasing consistently over the years. The gross profit margin for 2024 is approximately 69.8%, which is commendable and indicates efficient cost control. The net profit margin is 24.2% for 2024, reflecting solid profitability. However, the decline in EBIT margin from 25.9% in 2023 to 19.6% in 2024 suggests an increase in operating expenses relative to revenue.

Balance Sheet

The company has a low debt-to-equity ratio, with total debt being minimal compared to stockholders' equity, indicating a conservative approach to leverage. The equity ratio has improved to 91.2% in 2024, up from previous years, highlighting strong financial stability. However, a declining ROE from 12.2% in 2023 to 10.1% in 2024 may point to challenges in generating returns on equity.

Cash Flow

The absence of operating and free cash flow data for 2024 raises concerns about liquidity management. In previous years, there was a positive trend in free cash flow and operating cash flow, but the lack of data for 2024 makes it difficult to assess current cash flow health. Without this information, it's challenging to evaluate the company's operational efficiency and cash generation capabilities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	168.74M	164.10M	153.87M	136.82M	116.46M	88.47M
Gross Profit	114.59M	114.47M	106.50M	92.46M	81.17M	58.02M
EBITDA	36.74M	36.76M	53.97M	27.14M	8.31M	12.75M
Net Income	40.67M	39.72M	45.07M	18.49M	-4.44M	7.07M
Balance Sheet
Total Assets	445.80M	431.01M	410.14M	351.06M	268.53M	103.65M
Cash, Cash Equivalents and Short-Term Investments	248.59M	248.59M	256.21M	247.94M	175.89M	15.95M
Total Debt	4.43M	4.20M	7.46M	4.03M	67.69M	51.56M
Total Liabilities	35.82M	36.63M	40.73M	28.49M	85.42M	68.75M
Stockholders Equity	408.86M	393.31M	368.40M	322.57M	183.11M	34.90M
Cash Flow
Free Cash Flow	1.76M	1.84M	15.55M	20.10M	18.36M	8.91M
Operating Cash Flow	4.90M	13.11M	23.03M	23.43M	20.50M	12.67M
Investing Cash Flow	30.67M	8.65M	-52.31M	-169.32M	-5.22M	-11.24M
Financing Cash Flow	-6.56M	-18.96M	884.00K	57.44M	146.31M	-473.00K

OrbusNeich Medical Group Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.44
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6929, the sentiment is Positive. The current price of 4.44 is below the 20-day moving average (MA) of 4.55, below the 50-day MA of 4.49, and above the 200-day MA of 3.87, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 52.42 is Neutral, neither overbought nor oversold. The STOCH value of 55.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6929.

OrbusNeich Medical Group Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9997	―	€10.63B	17.45	23.40%	2.90%	6.51%	4.85%
1358	―	€2.16B	14.04	3.76%	6.67%	21.39%	-0.57%
1501	―	HK$5.26B	25.41	10.31%	1.00%	14.06%	3.02%
6929	―	HK$3.71B	11.71	10.35%	2.15%	11.06%	5.03%
1066	―	HK$25.46B	12.08	8.34%	4.23%	0.74%	2.13%
6699	―	HK$10.42B	218.04	―	―	―	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

OrbusNeich Medical Group Holdings Limited Corporate Events

OrbusNeich Reports Revenue Growth in 2025 Interim Results

OrbusNeich Medical Group Holdings Limited announced its interim results for the six months ending June 30, 2025, showing a 5.9% increase in revenue compared to the same period in 2024. Despite a slight decrease in profit before income tax, the company reported a 5.1% increase in profit attributable to owners, highlighting stable financial performance amidst rising costs and a competitive market environment.

OrbusNeich Declares Special Dividend of HKD 0.15 Per Share

OrbusNeich Medical Group Holdings Limited has announced a special cash dividend of HKD 0.15 per share, with the ex-dividend date set for September 18, 2025, and payment scheduled for October 6, 2025. This announcement may positively impact shareholder value and reflects the company’s strong financial position, potentially enhancing its attractiveness to investors.

OrbusNeich Announces Board Meeting to Discuss Interim Results

OrbusNeich Medical Group Holdings Limited has announced a board meeting scheduled for August 15, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend and other business matters, potentially impacting the company’s financial strategy and shareholder returns.